Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
Open Access
- 10 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 125 (2), 200-208
- https://doi.org/10.1038/s41416-021-01380-3
Abstract
Background This open-label, Phase 1b/2 study evaluated the highly selective MET inhibitor tepotinib in systemic anticancer treatment (SACT)-naive Asian patients with advanced hepatocellular carcinoma (aHCC) with MET overexpression. Methods In Phase 2b, tepotinib was orally administered once daily (300, 500 or 1,000 mg) to Asian adults with aHCC. The primary endpoints were dose-limiting toxicities (DLTs) and adverse events (AEs). Phase 2 randomised SACT-naive Asian adults with aHCC with MET overexpression to tepotinib (recommended Phase 2 dose [RP2D]) or sorafenib 400 mg twice daily. The primary endpoint was independently assessed time to progression (TTP). Results In Phase 1b (n = 27), no DLTs occurred; the RP2D was 500 mg. In Phase 2 (n = 90, 45 patients per arm), the primary endpoint was met: independently assessed TTP was significantly longer with tepotinib versus sorafenib (median 2.9 versus 1.4 months, HR = 0.42, 90% confidence interval: 0.26–0.70, P = 0.0043). Progression-free survival and objective response also favoured tepotinib. Treatment-related Grade ≥3 AE rates were 28.9% with tepotinib and 45.5% with sorafenib. Conclusions Tepotinib improved TTP versus sorafenib and was generally well tolerated in SACT-naive Asian patients with aHCC with MET overexpression. Trial registration ClinicalTrials.gov NCT01988493.Keywords
Funding Information
- Merck KGaA
- Merck KGaA, Darmstadt, Germany
This publication has 40 references indexed in Scilit:
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialThe Lancet Oncology, 2015
- The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer ModelsCancers, 2014
- GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer CellsACS Chemical Biology, 2013
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind METClinical Cancer Research, 2013
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyThe Lancet Oncology, 2012
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular CarcinomaClinical Cancer Research, 2012
- c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinomaJournal of Hepatology, 2011
- Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer PatientsJournal of Clinical Oncology, 2009
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008